Author of the publication

Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration

, , , , , , , , , , , , , and . Proceedings of the National Academy of Sciences of the United States of America, 113 (43): 12304-12309 (2016)
DOI: 10.1073/pnas.1605195113

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

 

Other publications of authors with the same name

Intrathymic dendritic cell-biased precursors promote human T cell lineage specification through IRF8-driven transmembrane TNF, , , , , , , , , and 12 other author(s). Nature immunology, 24 (3): 474-486 (2023)Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV, , , , , , , , , and 1 other author(s). mAbs, 9 (5): 831-843 (2017)A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells, , , , and . Scientific reports, (2021)Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format, , , , , , and . OncoImmunology, 5 (11): e1238540 (2016)Activatable bispecific liposomes bearing fibroblast activation protein directed single chain fragment/Trastuzumab deliver encapsulated cargo into the nuclei of tumor cells and the tumor microenvironment simultaneously, , , , , , , and . Acta biomaterialia, (2017)Fc-based Duokines : dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc), , , , , , and . OncoImmunology, 11 (1): 2028961 (2022)Bispecific antibodies, and . Science, 372 (6545): 916-917 (2021)Corrigendum to "Bispecific antibodies" Drug Discov. Today 20 (July (7)) (2015) 838-847, and . Drug Discovery Today, 24 (7): 1422 (2019)Correction to: https://doi.org/10.1016/j.drudis.2015.02.008.Pharmacokinetic Engineering of OX40-Blocking Anticalin Proteins Using Monomeric Plasma Half-Life Extension Domains, , , , , , , , , and 3 other author(s). Frontiers in pharmacology, (2021)An optimized antibody-single-chain TRAIL fusion protein for cancer therapy, , , , , , , , , and . mAbs, 8 (5): 879-891 (2016)